Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck's Keytruda Loss In Liver Cancer Could Be Gain For Rivals

Executive Summary

The drug demonstrates improvements in overall survival and progression-free survival, but not enough for success in KEYNOTE-240.


Related Content

Can-Fite Plans Phase III For Namodenoson, Despite Liver Cancer Trial Failure
Keytruda/Inlyta Data Stoke Competition In Kidney Cancer
Merck's Keytruda Lead Widens Over Competing Checkpoint Inhibitors
Lartruvo Phase III Fail Rocks Lilly Oncology Plans
Keeping Track: FDA's Review Actions Carry On During Shutdown
Keeping Track Of Approvals: Cancer, Cancer, And A Two-Week Cancer Review
First In 10 Years, But Lenvima's First-Line Liver Label Could Be Challenged Soon
Keytruda Clears Low Hurdle In Stage III Melanoma
Pipeline Watch: Phase III Starts For BL-8040, Trigriluzole, MIN-101
Avastin Loses Its Breast Cancer Claim; FDA’s Hamburg Opts For Withdrawal Over Restrictions


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts